Synnovation Therapeutics
Rob Casper has extensive experience in clinical operations, serving in various leadership roles, including Vice President, Head of Clinical Operations at Synnovation Therapeutics, and Vice President of Clinical Operations at Adaptive Phage Therapeutics and Altimmune, Inc. Previous positions include Senior Director of Clinical Operations at Kolon TissueGene, Inc. and Symbiomix Therapeutics, LLC. Rob Casper holds two Master of Science degrees in Developmental Psychology and Clinical Counseling and Applied Psychology from The Johns Hopkins University.
This person is not in any teams
This person is not in any offices
Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.